OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

more to come next week..........

last trade of the day.450k buy.................bodes well for the start Monday

Hi Midas -Unless everything you touch turns to gold it looks like a sell to me - even so it has been a great week and lets hope for more of the same

it's a sell between mms. institutions have been courted but i'd expect some profit taking on monday. all the good news i should think is out for a while but long term believe th sp will rise above 1 - the graph suggests a double top but who really believes in that balonie, apple - time to get out again?

No stock overhang..........plenty of buyers including institutions.........30p+ this week imho.

mostly red today, no news in the weekend press, I thought we may be getting a bid this morning.

Oh Pooh.

I sold a few this morning & then I saw the way things were going so I sold some more & cut right back to my core holding.

I saw it turn round again so I bought a few more again.
It dropped by more than the spread so that worked well.

It's hard to work out why this share was so strong last week, that's why I was poised to sell some this morning.

I don't know where we go from here so I'm keeping my eye on the trades to find out.

We have of course been here before - this time however, it is rebounding a little more quickly and that will please the chartists and those of us who show patience - having said that I bought at 15.6p so could have made good profit.

with the drop in price today, whats the resistance level?? back down to 20p again ???

probably.

20p is the first resistance level, 19p the next, based on the short-term triple bottom that we witnessed over the past month. Let's hope we don't get a triple witching hour at the same time or I'll have to make an appointment with my local optician!!!

or maybe it was 24

maybe so, but OXB has a tendency to upset the applecart and go south.

Iamole - I was stating the next resistance level if 24 did not hold. Fortunately there was a sharp upwards reaction which is good for long-term holders such as myself.

not looking good :(

With all the sells going through, and yet little change in the sp, I wonder whether they are being mopped up by an instituional buyer? Wishful thinking?

Well if they were, they've stopped now, oh dear here we go again...Why is OXB such a dog?!

I spoke too soon - I shall keep my mouth shut in future.

Looks like I was right to cut back my holding yesterday, now I'm watching for the next low for a buying opportunity.

ARIUS Anti-Cancer Antibodies and FunctionFIRST(TM) Platform Featured at AACR
Novel antibodies and unique discovery platform capture 6 presentation
slots

TORONTO, April 12 /CNW/ - ARIUS Research Inc. (TSX-VE: ARI) announced
today that it will present data on therapeutic anti-cancer antibody programs
generated from its FunctionFIRST(TM) platform, and results from its research
collaboration with Oxford BioMedica (LSE: OXB) at the 96th Annual Meeting of
the American Association for Cancer Research in Anaheim/Orange County, CA from
April 16-20, 2005.
ARIUS has substantially increased its pipeline of antibodies and cancer
targets over the last year, which is reflected in the record number of
presentations for this year. ARIUS will disclose the target and new data for a
family of highly effective anti-cancer antibodies in a series of three
presentations:

Abstract No. 2340: Identification and validation of CD63 as a new
therapeutic target. Monday April 18, 2005, 8:00 AM-12:00 PM, Section
Number: 26.

Abstract No. 2338: 3 unique antibodies demonstrate therapeutic effects
against CD63, a novel target for cancer therapy. Monday April 18, 2005
8:00 AM-12:00 PM, Section Number: 26.

Abstract No. 551: CD63 cancer antigen in multiple tumor types:
Targeting by the functional antibody AR7BD-33-11A results in anti-tumor
activity. Sunday April 17, 2005, 8:00 AM-12:00 PM, Section Number: 24.

Separately, ARIUS will address the need for multiple antibody therapies
to offer targeted options to the greatest number of patients and the
opportunity that exists to combine antibodies to pursue greater efficacy.

Abstract No. 693: Towards enabling personalized cancer drug therapy:
Functional monoclonal antibodies target overlapping populations of
human breast cancer and melanoma. Sunday April 17, 2005,
8:00 AM-12:00 PM, Section Number: 29.

ARIUS will add to the body of knowledge on its anti-cancer antibody,
ARH460-16-2 and release new data on how the antibody works through apoptosis
(inducing cell suicide) to kill cancer cells.

Abstract No. 1768: Functional monoclonal antibody, ARH460-16-2,
inhibits tumor growth and prolongs survival by inducing apoptosis
through CD44. Monday April 18, 2005, 8:00 AM-12:00 PM,
Section Number: 12.

Finally, ARIUS, in collaboration with their partner Oxford BioMedica,
will present the first results for the company in liver cancer, an important
and growing problem in Asia and other parts of the world affected by
hepatitis B, hepatitis C and cirrhosis of the liver.

Abstract No. 5138: Characterisation of a hepatocellular
carcinoma-specific antibody AR5LAC-23. Tuesday April 19, 2005,
1:00 PM-5:00 PM, Section Number: 30.

"We are excited by the information we are presenting at AACR this year.
This represents the culmination of several years' worth of work on an exciting
new cancer target, CD63. The excitement around CD63 is, of course, due to the
highly effective therapeutic antibodies that ARIUS has developed to treat
cancers that express this target. We are also presenting advances in our other
antibody programs which represent key contributions to the area of targeted
therapy in cancer. These include understanding how ARH460-16-2 works to
control cancer, and significantly prolong survival. We address how
combinations of anti-cancer antibodies can be used to target specific patient
groups who may benefit from using different ARIUS antibodies in conjunction
with those already being marketed. We are also very pleased to present
information on the target of a liver cancer specific antibody generated from
the FunctionFIRST(TM) platform. Liver cancer is one of the very lethal forms
of cancer that is highly prevalent in many parts of the world that desperately
requires a breakthrough. We believe that the target of AR5LAC-23 will be one
step towards that breakthrough," said Dr. Susan Hahn, Director of R&D at
ARIUS.
All sessions will be presented in Exhibit Hall B-D at the Anaheim
Convention Center. Full text of the abstracts can be obtained through AACR
(http://www.aacr.org/) by following the link labeled "96th Annual Meeting
2005" and then on the 2005 AACR Annual Meeting webpage "Access the 2005
Proceedings of the AACR and Online Itinerary Planner" and searching for ARIUS.